Jilin University and Jilin Agricultural University to Transfer GFPA Polysaccharide Technology for Lipid Regulation at RMB 30,000
Recently, Jilin University and Jilin Agricultural University released public notices on the transformation of scientific and technological achievements, proposing to adopt agreed pricing for the intended transfer of"A Grifola frondosa Purified Polysaccharide with Blood Lipid-Regulating Function and Its Preparation Method"Assignment of Relevant Patents toJilin Province Meiluo Biological Products Co., Ltd.Use, transfer fee is RMB30,000 yuan. The inventor of this patented technology isProfessor Wang Di and his team。
Wang Di:Professor at Jilin University. He received his Ph.D. from the Li Ka Shing Faculty of Medicine, The University of Hong Kong, in 2013 and was selected for the National High-Level Young Talents Program in 2020. His research primarily focuses on the efficacy screening and mechanism of action of natural products, as well as the secondary development of major traditional Chinese medicine and biological drug products. He has published 123 SCI-indexed original and review articles in international journals such as *Molecular Cancer*, *Science Advances*, *Clinical and Translational Medicine*, *Carbohydrate Polymers*, and *Journal of Neuroinflammation* (including 116 papers as first or corresponding author), with a cumulative impact factor of 653.9. Among these publications, 13 are in CAS Tier 1 journals and 52 in CAS Tier 2 journals, with an H-index of 23. He has co-edited eight textbooks/monographs and obtained 26 authorized invention patents (with eight commercialized). He has undertaken 24 national and provincial/ministerial-level projects, including sub-projects of the National Key R&D Program for Intergovernmental Scientific and Technological Innovation Cooperation, grants from the National Natural Science Foundation of China, major scientific and technological achievement transformation projects under Jilin Province’s “Double Ten Project,” key scientific and technological breakthrough projects in Jilin Province, special projects for medicine and health in Jilin Province, and special projects for industrial technology research and development in Jilin Province.
The present invention aims to prepare a substance with the functions of regulating blood lipids and treating obesity.Purified Polysaccharides from Grifola frondosa(GFPA), and clarifying its structural characteristics and application value, belonging to the field of pharmaceutical technology. Aiming at hyperlipidemia and obesity, we have developed a safe and effective natural active ingredient—purified polysaccharides from Grifola frondosa—to replace or supplement existing lipid-lowering Western drugs (such as statins), addressing their toxic side effects including rhabdomyolysis, gastrointestinal irritation, and abnormal liver enzymes.
Lipid Metabolism BalanceIt is key to maintaining human cardiovascular health. Hyperlipidemia, a common disorder caused by abnormal lipid metabolism, has become a major challenge in the global health sector.
With the widespread prevalence of high-fat, high-cholesterol diets, the incidence of hyperlipidemia has been rising year by year. The resulting lipid peroxidation causes damage to endothelial cells, thereby inducing severe cardiovascular and cerebrovascular diseases such as atherosclerosis, coronary heart disease, and hypertension. Hyperlipidemia and its complications account for a significant proportion of global mortality rates, reaching as high as50%, posing a significant threat to patients' lives and health.
Meanwhile, obesity associated with high-fat diets has become increasingly prominent. Metabolic disturbances triggered by excessive accumulation of adipose tissue further elevate the risk of dyslipidemia, creating a vicious cycle of “obesity–hyperlipidemia” that severely impairs patients’ quality of life.
This population urgently requires safe and effective interventions that can regulate lipid levels, reduce fat accumulation, and avoid causing additional harm to the body. For instance, middle-aged and elderly patients with hyperlipidemia require long-term lipid management to prevent cardiovascular events, while individuals with obesity seek to improve metabolic indicators and reduce the risk of complications while losing weight.
Currently, the mainstream clinical lipid-lowering regimens primarily adoptStatins, Niacins, Fibratesand other Western medicines. Although such regimens can, to a certain extent, reduce the levels of atherogenic lipoproteins or increase high-density lipoprotein (HDL) levels, they are significantly limited by severe toxic side effects. Long-term use of these medications is prone to causing adverse reactions such as rhabdomyolysis, gastrointestinal irritation, and abnormal liver enzymes, forcing some patients to discontinue treatment due to intolerance.
However, although traditional natural products used for lipid regulation have relatively minor toxic side effects, they generally suffer from issues such as unclear active ingredients, low purity, and unstable lipid-lowering efficacy, making it difficult to meet the precise requirements of clinical treatment.
Furthermore, most existing therapeutic interventions target either lipid regulation or obesity control alone. There is a lack of natural active pharmaceutical agents capable of simultaneously achieving the dual effects of “lipid modulation + weight reduction,” thereby failing to comprehensively address the health challenges synergistically induced by “hyperlipidemia–obesity.”
In light of these pain points, there is an urgent market need for a novel product derived from natural sources, with high safety, well-defined purity, and dual efficacy in lipid regulation and obesity treatment, to fill the gaps in existing therapeutic options.
This technology utilizes natural fruiting bodies of *Grifola frondosa* (Maitake) as raw materials. The purified polysaccharides prepared are natural bioactive components, ensuring product safety at its source. Animal studies have confirmed that these polysaccharides do not exhibit significant toxic side effects, thereby completely avoiding the adverse reactions commonly associated with conventional lipid-lowering Western medicines such as statins and niacin, including rhabdomyolysis, gastrointestinal irritation, and abnormal liver enzymes. Furthermore, UV spectral analysis has verified that the polysaccharides are free from impurities such as proteins and nucleic acids, further reducing potential risks of allergy and metabolic disorders.
Technical outcomes possess bothRegulating Blood Lipids and Treating Obesityits dual core efficacy achieves a synergistic intervention of “lipid regulation + weight loss.” In terms of lipid regulation, it significantly reduces serum levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), while increasing levels of high-density lipoprotein cholesterol (HDL-C), which has cardioprotective effects, thereby comprehensively improving lipid biochemical profiles. In the treatment of obesity, it effectively reduces the number and volume of lipid droplets in adipose tissue, alleviating lipid accumulation and infiltration induced by a high-fat diet, with demonstrated improvements in three types of adipose tissue in mice: epididymal white adipose tissue (eWAT), inguinal white adipose tissue (iWAT), and retroperitoneal white adipose tissue (rWAT).
This technology has established“Defatting - Water Extraction - Deproteinization - Alcohol Precipitation - Ion Exchange Chromatography - Gel Filtration Chromatography - Freeze Drying”standardized preparation process with well-defined process parameters and strong reproducibility. High-efficiency extraction and purification were achieved by optimizing key parameters such as the solid-to-liquid ratio, extraction temperature, and elution concentration.
Meanwhile, the product exhibits highly uniform structure and properties. Its molecular weight range (4,000–6,000 kDa, optimal 4,188.9 kDa), monosaccharide composition and molar ratio (glucose:galactose:fucose = 99.73:0.17:0.10), and specific chemical structure were clearly defined. Comprehensive characterization was performed using multiple techniques, including HPLC, infrared spectroscopy, and nuclear magnetic resonance, thereby ensuring the stability and controllability of product quality.
In addition to the highly popular in recent years,GLP-1, and the classicStatins, driven by the sustained growth in market demand for lipid-lowering and weight-loss interventions, multiple technological pathways—including chemical drugs and natural active ingredients—are developing in parallel.
Furthermore, in the field of Grifola frondosa extract,Zhejiang Fangge Pharmaceutical Co., Ltd.Grifola frondosa Polysaccharide Capsules are a dietary supplement with Grifola frondosa polysaccharides as the core active ingredient. The product utilizes a water extraction and alcohol precipitation process to extract polysaccharides from the fruiting bodies of Grifola frondosa, primarily aiming to assist in lowering blood lipid levels and enhancing immunity.